Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab for Prevention of Persistent Post-Traumatic Headache
NCT04098250Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jan 2021
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of erenumab in post-traumatic headache (PTH), sponsored by Mayo Clinic. Started Jan 2021; status: completed.
02
Drugs
erenumab
03
Conditions
post-traumatic headache (PTH)
Beyond the preview
Go deeper on NCT04098250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04098250.